Last reviewed · How we verify
Extended-release naltrexone injection, 380 mg
Extended-release naltrexone injection, 380 mg is a Small molecule drug developed by Akyso Therapeutics, LLC. It is currently in Phase 1 development.
At a glance
| Generic name | Extended-release naltrexone injection, 380 mg |
|---|---|
| Sponsor | Akyso Therapeutics, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- anxiety
- headache
- injection site reaction
- toothache
- abdominal pain
- anxiousness
- depression
- fatigue or decreased energy
- restlessness
- back pain
- common cold
Key clinical trials
- iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers (PHASE1)
- Naltrexone in AUD Reward Drinkers (PHASE4)
- Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia (PHASE1)
- Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults (PHASE4)
- Vivitrol Treatment for Cannabis Use Disorder (PHASE2)
- Inpatient Single Dose Interventions for Alcohol Use Disorder (EARLY_PHASE1)
- Biomarkers of Injectable Extended Release Naltrexone Treatment (PHASE4)
- Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended-release naltrexone injection, 380 mg CI brief — competitive landscape report
- Extended-release naltrexone injection, 380 mg updates RSS · CI watch RSS
- Akyso Therapeutics, LLC portfolio CI
Frequently asked questions about Extended-release naltrexone injection, 380 mg
What is Extended-release naltrexone injection, 380 mg?
Extended-release naltrexone injection, 380 mg is a Small molecule drug developed by Akyso Therapeutics, LLC.
Who makes Extended-release naltrexone injection, 380 mg?
Extended-release naltrexone injection, 380 mg is developed by Akyso Therapeutics, LLC (see full Akyso Therapeutics, LLC pipeline at /company/akyso-therapeutics-llc).
What development phase is Extended-release naltrexone injection, 380 mg in?
Extended-release naltrexone injection, 380 mg is in Phase 1.
What are the side effects of Extended-release naltrexone injection, 380 mg?
Common side effects of Extended-release naltrexone injection, 380 mg include Nausea, anxiety, headache, injection site reaction, toothache, abdominal pain.